Increased Risk For Patients With Newly Diagnosed Type 2 Diabetes According To Recent Medical Research Study
Use of dipeptidyl peptidase-4 inhibitors (DPP-4i) diabetes medicines is associated with increased risks for pancreatic cancer in patients with newly diagnosed type 2 diabetes, according to an August 20, 2019 article published online by the Diabetes Care medical journal.
These diabetes medicines are in the dipeptidyl peptidase-4 (DPP-4) inhibitor drug class:
Kombiglyze XR (saxagliptin and metformin)
Qtern (dapagliflozin and saxagliptin)
Kazano (alogliptin and metformin)
Oseni (alogliptin and pioglitazone)
Jentadueto (linagliptin and metformin HCl)
Glyxambi (linagliptin and empagliflozin)
From an August 2019 Healio Endocrine Today news report, "DPP-IV inhibitors may increase risk for pancreatic cancer", we get some commentary from the medical researchers who conducted this drug safety study:
"DPP-IV inhibitors are widely used, well-tolerated antidiabetic agents that offer several advantages in clinical settings, especially for medically fragile populations, owing to their favorable efficacy and safety profile,” the researchers told Endocrine Today. “However, there is a concern that DPP-IV inhibitors may adversely impact the exocrine pancreas, owing to their pleiotropic effects. Thus, the pancreatic safety of incretin-based therapies is an important clinical issue to more safely prescribe this useful antidiabetic medication.”
Strictly Confidential, No Obligation.
From the Abstract for this Diabetes Care article, "Nationwide Trends in Pancreatitis and Pancreatic Cancer Risk Among Patients With Newly Diagnosed Type 2 Diabetes Receiving Dipeptidyl Peptidase-4 Inhibitors", we get the following information:
- OBJECTIVE: Dipeptidyl peptidase-4 inhibitors (DPP-4i) are useful incretin-based antidiabetes drugs. However, there is a concern that DPP-4i may adversely impact the exocrine pancreas, owing to their pleiotropic effects. In this study, we investigated whether DPP-4i are associated with pancreatitis and pancreatic cancer using a nationwide population-based cohort study.
- RESULTS: Out of 33,208 subjects, 10,218 were new users of DPP-4i and 22,990 were new users of other antidiabetes drugs. DPP-4i significantly increased the risks of pancreatitis (adjusted hazard ratio [aHR] 1.24, 95% CI 1.01–1.52; P = 0.037) and pancreatic cancer (aHR 1.81, 95% CI 1.16–2.82; P = 0.009) with a 6-month drug use lag period. The risk of pancreatitis and pancreatic cancer was generally consistent in the first 12 months and 1 year after the initial prescription without showing an increasing trend according to exposure duration.
- CONCLUSIONS: DPP-4i use is associated with increased risks of pancreatitis and pancreatic cancer in patients with newly diagnosed type 2 diabetes. However, the absence of increasing trend according to exposure duration suggests the chances of reverse causality, and long-term pancreatic safety of DPP-4i has to be further investigated.
We will watch for additional medical research concerning the possible link between pancreatic cancer and DPP-4 inhibitor diabetes drugs such as Onglyza (saxagliptin), Nesina (alogliptin), and Tradjenta (linagliptin).
DrugInjuryLaw.com: Medical & Legal Information About Drug Side Effects (All website content by attorney Tom Lamb)
Drug Injury Case Evaluation - Free. Confidential. No Obligation. (Case review is done by attorney Tom Lamb)